Enveda reports promising Phase 1 data for oral drug that mimics exercise to preserve muscle during weight loss

Enveda, a biotech based in Boulder, Colorado, announced Phase 1 results for its oral candidate ENV-308, a chemically engineered version of the metabolite lactate phenylalanine (lac-phe). The metabolite was identified in a 2022 Nature study for its ability to suppress appetite and reduce obesity in animal models.

The drug is designed to act as a leptin sensitizer and to maintain lean muscle mass, a challenge often seen with GLP‑1 therapies where patients lose muscle along with fat during weight loss.

Early data suggest the compound was well tolerated and showed signals of appetite suppression, but the trial was small and further studies will be required to confirm efficacy and safety.